Biointron

Founded in 2012, we are a biotechnology CRO with expertise in antibody discovery. We have served biotech/biopharma companies worldwide.

[Biointron @Biointron2012]

💵 Whitehawk Therapeutics expands ADC pipeline with options for up to five ADC Programs, including dual-payload variations from Hangzhou DAC. https://t.co/RtUmyXfIG4

[Biointron @Biointron2012]

Roundup of #antibody #biotech deals in May 2026 👇

🤝 @pfizer and @Innovent_2011 strike $10.5B deal to collaborate on development of up to 12 antibody drugs (ADCs & multispecifics). https://t.co/5AeBEQfj3n

[Biointron @Biointron2012]

🤝 Delos Capital and @ApBiosciences launch collaboration to create new biotech companies focused on autoimmune diseases using bi- and tri-specific antibodies. https://t.co/GrxIZaZbYn

[Biointron @Biointron2012]

🧬 Can antibodies be used to selectively turn down T cell responses? A new study by @UOsaka_en introduces immune-induced TCR-like antibodies (iTabs), and their potential role in controlling antigen-specific immunity.

#Biointron #Antibodies #Research
https://t.co/H2K0FhPsLz

[Biointron @Biointron2012]

𝐎𝐧𝐥𝐲 𝟏 𝐰𝐞𝐞𝐤 𝐭𝐢𝐥𝐥 𝐭𝐡𝐞 𝟑𝟏𝐬𝐭 𝐂𝐁𝐀 𝐀𝐧𝐧𝐮𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞!

📅 Date: June 06, 2026
📍 Location: Marriott Washingtonian Center | Gaithersburg, MD

Register for a 1-on-1 time with us here:
🔗 https://t.co/eloisxKLeI

#Biointron

[Biointron @Biointron2012]

🎉 Siyu Sun, PhD (@SynapseBV), has been selected as Biointron’s Q2 2026 Travel Grant recipient!

📍 Dr. Sun will be presenting at ISTH Congress on: Targeting fibrin fiber lateral expansion remodels clot mechanics, contraction and fibrin-dependent thrombin
https://t.co/T5Fbo4qavU

[Biointron @Biointron2012]

🔬 New insights into bispecific antibody assembly, using chemical conjugation strategies: bioorthogonal click chemistry.

Useful as a rapid, tunable, and modular platform for early-stage multispecific antibody development.

#Biointron #Antibodies
https://t.co/XyFXyevEwM